Wells Fargo & Company Reiterates Equal Weight Rating for aTyr Pharma (NASDAQ:ATYR)

Key Points

• aTyr Pharma received an "Equal Weight" rating from Wells Fargo, while several other analysts have downgraded their ratings recently, indicating mixed sentiment in the market.
• The company reported a loss of ($0.22) EPS for its last quarter, missing expectations and projecting an overall EPS of -0.91 for the current year.
• Institutional investors hold a significant stake in aTyr Pharma, owning 61.72% of the company's stock, with notable increases in positions by several hedge funds recently.

aTyr Pharma (NASDAQ:ATYR - Get Free Report)'s stock had its "equal weight" rating restated by stock analysts at Wells Fargo & Company in a research report issued to clients and investors on Monday, September 15th, MarketBeat reports.

ATYR has been the subject of several other reports. Leerink Partners reiterated a "market perform" rating on shares of aTyr Pharma in a research report on Monday, September 15th. Jefferies Financial Group boosted their price target on aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, August 22nd. Wall Street Zen lowered aTyr Pharma from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. HC Wainwright lowered aTyr Pharma from a "buy" rating to a "neutral" rating in a research note on Monday, September 15th. Finally, Cantor Fitzgerald lowered aTyr Pharma from an "overweight" rating to a "neutral" rating in a research note on Monday, September 15th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $23.25.

aTyr Pharma Trading Down 5.7%

ATYR stock traded down $0.06 during trading on Monday, hitting $0.99. The company had a trading volume of 9,374,207 shares, compared to its average volume of 4,304,973. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. aTyr Pharma has a one year low of $0.95 and a one year high of $7.29. The business has a 50-day moving average of $4.75 and a 200-day moving average of $4.27. The stock has a market cap of $97.02 million, a PE ratio of -1.24 and a beta of 1.01.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.22) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). Research analysts predict that aTyr Pharma will post -0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On aTyr Pharma

Institutional investors have recently modified their holdings of the company. Group One Trading LLC acquired a new position in shares of aTyr Pharma during the fourth quarter worth approximately $26,000. California State Teachers Retirement System acquired a new position in shares of aTyr Pharma during the second quarter worth approximately $28,000. Y Intercept Hong Kong Ltd acquired a new position in shares of aTyr Pharma during the first quarter worth approximately $38,000. Two Sigma Advisers LP bought a new stake in aTyr Pharma during the fourth quarter worth $44,000. Finally, Ameritas Investment Partners Inc. bought a new stake in aTyr Pharma during the second quarter worth $45,000. 61.72% of the stock is owned by institutional investors and hedge funds.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.